GLP-1 receptor agonists, the drug class that includes semaglutide, have moved well beyond their original role in glycaemic management. According to a comment published in The Lancet, the indications for these medicines are continuing to expand, with evidence now established in several metabolic and cardiovascular conditions.
A Growing List of Indications
Research has demonstrated benefits of GLP-1 receptor agonists in chronic kidney disease among people with type 2 diabetes. The drug class has also shown positive effects in obesity-related heart failure, knee osteoarthritis, and metabolic dysfunction-associated steatohepatitis — a form of liver disease linked to metabolic dysfunction. Taken together, these findings reflect a pattern of benefit that extends considerably beyond weight and blood sugar control.
Central Nervous System: A Less Settled Picture
The Lancet comment situates a newer area of inquiry — the potential role of GLP-1 receptor agonists in Alzheimer's disease — within this broader landscape. However, the piece characterises the evidence in central nervous system disorders as less consistent than what has been observed in metabolic and cardiovascular settings.
Some signals of potential benefit have emerged in specific neurological and psychiatric contexts. The Lancet piece notes indications of possible effect in idiopathic intracranial hypertension and in alcohol use disorder. The picture in Parkinson's disease, however, is described as uncertain.
Alzheimer's Disease Under Investigation
The comment was published in the context of the evoke and evoke+ trials, which examined semaglutide as a potential intervention in Alzheimer's disease. The piece does not report definitive conclusions from those trials but frames the question within the uneven body of evidence for GLP-1 receptor agonists in brain-related conditions.
The inconsistency noted across CNS research may reflect the biological complexity of the brain relative to peripheral organs, though the Lancet comment does not speculate on mechanisms beyond what the trial data support.
What This Means for the Field
The expanding investigation of GLP-1 receptor agonists across disease areas reflects a broader scientific interest in whether the metabolic and anti-inflammatory properties of this drug class translate into benefits outside their established indications. In conditions such as kidney disease and heart failure, that translation appears to have been demonstrated. In neurological disorders, the research remains at an earlier and more ambiguous stage, according to The Lancet.
Whether semaglutide or related compounds will ultimately show a consistent, clinically meaningful effect in Alzheimer's disease remains an open question in the literature.